LRP5 (D5G4) Rabbit mAb

• 产品编号：CST-5440S      品牌：CST       原厂货号：5440S
• 产品分类：抗体 > 一抗 > 蛋白特异性一抗
• 应用分类：

描述：

LRP5 (D5G4)Rabbit mAb 兔单抗识别内源性的总LRP5蛋白。此单克隆抗体由人源LRP5重组蛋白（胞外区域）免疫动物产生。LRP5和LRP6是单次跨膜蛋白，隶属于低密度脂蛋白受体（LDLR）相关蛋白家族。不同于其他LDLR家族成员，LRP5和LRP6胞外域有4个EGF和3个LDLR重复序列，胞浆域富含脯氨酸（1）。它们在经典Wnt/β-catenin信号通路中作为Wnt的共同受体（2,3）。LRP5和LRP6高度同源并且在发育过程中有多种作用（4,5）。LRP5和LRP6的活性在与Dickkopf (DKK) 家族某些蛋白结合后被抑制（6,7）。Wnt信号通路被激活后，LRP6可以被如GSK-3和CK1之类的激酶在多个位点被磷酸化，例如1479位苏氨酸，1490位丝氨酸和1493位苏氨酸（8-10）。磷酸化的LRP6招募axin蛋白到膜上以激活β-catenin信号通路（8-10）。LRP5蛋白参与骨稳态调节。LPR5的多态性和突变与骨骼疾病相关，如骨质疏松-假神经胶质瘤综合症以及高骨密度症[11-13]。此外，在甲亢功能亢进肿瘤和乳腺癌的病人中也发现了LPR5的突变(14,15).

1. Brown, S.D. et al. (1998) Biochem. Biophys. Res. Commun. 248, 879-888.
2. Pinson, K.I. et al. (2000) Nature 407, 535-538.
3. Tamai, K. et al. (2000) Nature 407, 530-535.
4. Kelly, O.G. et al. (2004) Development 131, 2803-2815.
5. He, X. et al. (2004) Development 131, 1663-1677.
6. Semënov, M.V. et al. (2001) Curr Biol 11, 951-61.
7. Bafico, A. et al. (2001) Nat. Cell Biol. 3, 683-668.
8. Tamai, K. et al. (2004) Mol. Cell 13, 149-156.
9. Zeng, X. et al. (2005) Nature 438, 873-877.
10. Davidson, G. et al. (2005) Nature 438, 867-872.
11. Levasseur, R. et al. (2005) Joint Bone Spine 72, 207-14.
12. Ferrari, S.L. et al. (2005) Curr Opin Lipidol 16, 207-14.
13. Balemans, W. and Van Hul, W. (2007) Endocrinology 148, 2622-9.
14. Björklund, P. et al. (2007) PLoS Med 4, e328.
15. Björklund, P. et al. (2009) PLoS One 4, e4243.

原厂资料：

Specificity / Sensitivity

LRP5 (D5G4) Rabbit mAb detects endogenous levels of total LRP5 protein.

Source / Purification

Monoclonal antibody is produced by immunizing animals with a recombinant human LRP5 protein (extracellular region).

Background

LRP5 and LRP6 are single-pass transmembrane proteins belonging to the low-density lipoprotein receptor (LDLR)-related protein family. Unlike other members of the LDLR family, LRP5 and LRP6 have four EGF and three LDLR repeats in the extracellular domain, and proline-rich motifs in the cytoplasmic domain (1). They function as co-receptors for Wnt and are required for the canonical Wnt/β-catenin signaling pathway (2,3). LRP5 and LRP6 are highly homologous and have redundant roles during development (4,5). The activity of LRP5 and LRP6 can be inhibited by the binding of some members of the Dickkopf (DKK) family of proteins (6,7). Upon stimulation with Wnt, LRP6 is phosphorylated at multiple sites including Thr1479, Ser1490, and Thr1493 by kinases such as GSK-3 and CK1 (8-10). Phosphorylated LRP6 recruits axin to the membrane and presumably activates β-catenin signaling (8-10).

LRP5 is involved in the regulation of bone homeostasis. Mutations and polymorphisms in LPR5 are associated with bone diseases like osteoporosis-pseudoglioma syndrome and high-bone-mass disorders (11-13). In addition, mutations in LRP5 are found in patients with hyperparathyroid tumor and breast cancer (14,15).

1. Brown, S.D. et al. (1998) Biochem. Biophys. Res. Commun. 248, 879-888.
2. Pinson, K.I. et al. (2000) Nature 407, 535-538.
3. Tamai, K. et al. (2000) Nature 407, 530-535.
4. Kelly, O.G. et al. (2004) Development 131, 2803-2815.
5. He, X. et al. (2004) Development 131, 1663-1677.
6. Semënov, M.V. et al. (2001) Curr Biol 11, 951-61.
7. Bafico, A. et al. (2001) Nat. Cell Biol. 3, 683-668.
8. Tamai, K. et al. (2004) Mol. Cell 13, 149-156.
9. Zeng, X. et al. (2005) Nature 438, 873-877.
10. Davidson, G. et al. (2005) Nature 438, 867-872.
11. Levasseur, R. et al. (2005) Joint Bone Spine 72, 207-14.
12. Ferrari, S.L. et al. (2005) Curr Opin Lipidol 16, 207-14.
13. Balemans, W. and Van Hul, W. (2007) Endocrinology 148, 2622-9.
14. Björklund, P. et al. (2007) PLoS Med 4, e328.
15. Björklund, P. et al. (2009) PLoS One 4, e4243.

注意事项：

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150
mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02%
sodium azide. Store at –20°C. Do not aliquot the antibody